INTERLEUKIN 2
데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
268535-76-8개요Cetus has introduced a stable rDNA interleukin-2 (rIL-2) for the treatment of renal cell carcinoma. Recent studies showed that rIL-2 in combination with lymphokine activated killer cells or tumor infiltrating lymphocytes induced regression or partial regression in patients with advanced metastatic cancers.
정의A type of biological response modifier (a substance that can improve the body’s natural response to disease). It stimulates the growth of certain disease-fighting blood cells in the immune system. Also called IL-2.